C. K. CHU

2.6k total citations
61 papers, 2.2k citations indexed

About

C. K. CHU is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, C. K. CHU has authored 61 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 42 papers in Infectious Diseases, 22 papers in Virology and 21 papers in Epidemiology. Recurrent topics in C. K. CHU's work include HIV/AIDS drug development and treatment (41 papers), HIV Research and Treatment (22 papers) and Biochemical and Molecular Research (11 papers). C. K. CHU is often cited by papers focused on HIV/AIDS drug development and treatment (41 papers), HIV Research and Treatment (22 papers) and Biochemical and Molecular Research (11 papers). C. K. CHU collaborates with scholars based in United States, Taiwan and Netherlands. C. K. CHU's co-authors include Raymond F. Schinazi, Deborah Cannon, Dennis C. Liotta, A. McMillan, Lak Shin Jeong, Joseph Warren Beach, Patrick Van Roey, S. Balakrishna Pai, Ying‐Chih Cheng and F. Douglas Boudinot and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Hepatology.

In The Last Decade

C. K. CHU

60 papers receiving 2.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
C. K. CHU United States 21 1.4k 869 792 769 582 61 2.2k
J P Sommadossi United States 21 1.1k 0.8× 774 0.9× 666 0.8× 621 0.8× 326 0.6× 49 2.0k
Joseph A. Martin United Kingdom 21 1.0k 0.7× 784 0.9× 388 0.5× 635 0.8× 582 1.0× 42 2.1k
Piet Wigerinck Belgium 19 1.1k 0.8× 438 0.5× 421 0.5× 768 1.0× 439 0.8× 44 1.8k
George A. Freeman United States 16 1.1k 0.8× 645 0.7× 409 0.5× 809 1.1× 549 0.9× 26 2.0k
Lotta Vrang Sweden 26 1.2k 0.9× 709 0.8× 540 0.7× 795 1.0× 667 1.1× 78 2.3k
Zhengqiang Wang United States 28 943 0.7× 741 0.9× 461 0.6× 731 1.0× 684 1.2× 84 2.0k
Sudthida Vasavanonda United States 16 1.5k 1.1× 488 0.6× 217 0.3× 1.3k 1.6× 481 0.8× 27 2.1k
Neil R. Hartman United States 19 1.1k 0.8× 503 0.6× 454 0.6× 917 1.2× 163 0.3× 41 1.9k
R. F. SCHINAZI United States 16 670 0.5× 345 0.4× 469 0.6× 410 0.5× 268 0.5× 33 1.3k
Mark W. Stahlhut United States 21 656 0.5× 600 0.7× 390 0.5× 252 0.3× 264 0.5× 45 1.7k

Countries citing papers authored by C. K. CHU

Since Specialization
Citations

This map shows the geographic impact of C. K. CHU's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. K. CHU with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. K. CHU more than expected).

Fields of papers citing papers by C. K. CHU

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. K. CHU. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. K. CHU. The network helps show where C. K. CHU may publish in the future.

Co-authorship network of co-authors of C. K. CHU

This figure shows the co-authorship network connecting the top 25 collaborators of C. K. CHU. A scholar is included among the top collaborators of C. K. CHU based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. K. CHU. C. K. CHU is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
CHU, C. K., et al.. (2025). Intergenerational living and aging in place: New Taipei City. 40(4). 51–77. 1 indexed citations
2.
Rawal, Ravindra K., et al.. (2015). Mechanism of Adefovir, Tenofovir and Entecavir Resistance: Molecular Modeling Studies of How A Novel Anti-HBV Agent (FMCA) Can Overcome the Drug Resistance. Current Medicinal Chemistry. 22(34). 3922–3932. 7 indexed citations
3.
Singh, Uma S., Joost J. van den Oord, Jan Balzarini, et al.. (2013). Activity and Mechanism of Action of HDVD, a Novel Pyrimidine Nucleoside Derivative with High Levels of Selectivity and Potency against Gammaherpesviruses. Journal of Virology. 87(7). 3839–3851. 21 indexed citations
4.
CHU, C. K., Yun Jin, Robert O. Baker, & John W. Huggins. (2003). Antiviral activity of cyclopentenyl nucleosides against orthopox viruses (Smallpox, monkeypox and cowpox). Bioorganic & Medicinal Chemistry Letters. 13(1). 9–12. 30 indexed citations
5.
6.
7.
Witcher, Jennifer, F. Douglas Boudinot, B. H. Baldwin, et al.. (1997). Pharmacokinetics of 1-(2-fluoro-5-methyl-beta-L-arabinofuranosyl)uracil in woodchucks. Antimicrobial Agents and Chemotherapy. 41(10). 2184–2187. 17 indexed citations
8.
Rajagopalan, Prabhu, Zhiling Gao, C. K. CHU, et al.. (1995). High-performance liquid chromatographic determination of (−)-β-d-2,6-diaminopurine dioxolane and its metabolite, dioxolane guanosine, using ultraviolet and on-line radiochemical detection. Journal of Chromatography B Biomedical Sciences and Applications. 672(1). 119–124. 3 indexed citations
9.
Zhao, Yufen, et al.. (1995). Asymmetric Synthesis of Cyclopropyl Carbocyclic Nucleosides. Nucleosides Nucleotides & Nucleic Acids. 14(3). 303–305. 4 indexed citations
10.
CHU, C. K., Tianwei Ma, Kirupa Shanmuganathan, et al.. (1995). Use of 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil as a novel antiviral agent for hepatitis B virus and Epstein-Barr virus. Antimicrobial Agents and Chemotherapy. 39(4). 979–981. 192 indexed citations
11.
Schinazi, Raymond F., Satyanarayana Nampalli, Kirupa Shanmuganathan, et al.. (1993). 1,3-Dioxolanylpurine nucleosides (2R,4R) and (2R,4S) with selective anti-HIV-1 activity in human lymphocytes. Journal of Medicinal Chemistry. 36(1). 30–37. 78 indexed citations
12.
Islam, Qamrul, James M. Gallo, F. Douglas Boudinot, et al.. (1993). Brain Targeting of anti-HIV Nucleosides: Ether Prodrugs of 3′-Azido-2′,3′-Dideoxyuridine (AZdU) and 3′-Azido-3′-Deoxythymidine (AZT). Antiviral chemistry & chemotherapy. 4(5). 263–269. 3 indexed citations
13.
Boudinot, F. Douglas, et al.. (1991). Dose-Dependent Pharmacokinetics of 3′-azido-2′,3′-dideoxyuridine in Rats. Antiviral chemistry & chemotherapy. 2(1). 17–22. 3 indexed citations
14.
Schinazi, Raymond F., C. K. CHU, B. Eriksson, et al.. (1990). Antiretroviral Activity, Biochemistry, and Pharmacokinetics of 3′‐Azido‐2′,3′‐Dideoxy‐5‐Methylcytidinea. Annals of the New York Academy of Sciences. 616(1). 385–397. 14 indexed citations
15.
16.
Williams, Gary J., Clarence Colby, Raymond F. Schinazi, et al.. (1990). The Cellular Metabolism of AzdU. Annals of the New York Academy of Sciences. 616(1). 620–623. 2 indexed citations
17.
CHU, C. K., et al.. (1989). General syntheses of 2',3'-dideoxynucleosides and 2',3'-didehydro-2',3'-dideoxynucleosides. The Journal of Organic Chemistry. 54(9). 2217–2225. 104 indexed citations
18.
Gallo, James M., et al.. (1989). Comparative pharmacokinetics of 3'-azido-3'-deoxythymidine (AZT) and 3'-azido-2',3'-dideoxyuridine (AZddU) in mice.. Drug Metabolism and Disposition. 17(6). 590–594. 37 indexed citations
19.
CHU, C. K., U. REICHMAN, K. A. WATANABE, & Jack J. Fox. (1977). Nucleosides. 104. Synthesis of 4-amino-5-(D-ribofuranosyl)pyrimidine C-nucleosides from 2-(2,3-O-isopropylidene-5-O-trityl-D-ribofuranosyl)acetonitrile. The Journal of Organic Chemistry. 42(4). 711–714. 20 indexed citations
20.
WATANABE, K. A., et al.. (1976). Nucleosides—XCV. Tetrahedron. 32(13). 1493–1495. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by J P Sommadossi Breakdown of academic impact, for papers by Joseph A. Martin Breakdown of academic impact, for papers by Piet Wigerinck Breakdown of academic impact, for papers by George A. Freeman Breakdown of academic impact, for papers by Lotta Vrang Breakdown of academic impact, for papers by Zhengqiang Wang Breakdown of academic impact, for papers by Sudthida Vasavanonda Breakdown of academic impact, for papers by Neil R. Hartman Breakdown of academic impact, for papers by R. F. SCHINAZI Breakdown of academic impact, for papers by Mark W. Stahlhut
Rankless by CCL
2026